



Evidence reviews

Evidence review

Published: 31 March 2022

Last updated: 31 March 2022

www.nice.org.uk

Evidence for the 2022 recommendations can be found in the <u>evidence review on</u> <u>pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes, continuous glucose monitoring in adults with type 2 diabetes and periodontal treatment to improve diabetic control in adults with type 1 or type 2 diabetes.</u>

Evidence for the 2021 recommendations can be found in the <u>evidence review on SGLT2</u> inhibitors for people with chronic kidney disease and type 2 diabetes.

In 2018 we reviewed the evidence for SGLT2 inhibitors and GLP-1 mimetics, and made no new recommendations. See the <u>evidence review on SGLT2 inhibitors and GLP-1</u> <u>mimetics</u> for more information.

Evidence for the 2009 and 2015 recommendations can be found in the 2015 full guideline on type 2 diabetes in adults, and supporting appendices:

- 2015 full guideline on type 2 diabetes in adults
- Appendix A: Guideline Development Groups & Declarations of Interest
- Appendix B: Scopes
- Appendix C: Search strategies and review protocols
- Appendix D: GRADE tables and meta-analysis result
- Appendix E: Evidence tables
- Appendix F: Full health economics report
- Appendix G: NICE guideline CG66 deleted text
- Appendix H: NICE guideline CG87 deleted text
- Appendix I: NICE guideline CG87 deleted appendix
- Appendix J: NMA results and input data
- Appendix K: WinBUGS code
- Appendix L: Excluded studies

See also the 2019 surveillance report on diabetes:

- 2019 surveillance of diabetes (NICE guidelines NG17, NG18, NG19 and NG28)
- Appendix A1: Summary of evidence from surveillance (NG17)
- Appendix B1: Stakeholder consultation comments table (NG17)
- Appendix A2: Summary of evidence from surveillance (NG28)
- Appendix B2: Stakeholder consultation comments table (NG28)
- Appendix A3: Summary of evidence from surveillance (NG18)
- Appendix B3: Stakeholder consultation comments table (NG18)
- Appendix A4: Summary of evidence from surveillance (NG19)
- Appendix B4: Stakeholder consultation comments table (NG19)